ReviewCNS neuroscience & therapeutics2026
The Role of γδ T Cells in Ischemic Stroke: Insights From the Perspective of the Brain-Gut Axis.
Review in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundStroke is a leading cause of disability and mortality worldwide, with ischemic stroke accounting for approximately 87% of all cases. Despite advances in reperfusion therapy, effective treatments targeting secondary neuroinflammation remain limited. Accumulating evidence indicates that γδ T cells, particularly through the production of interleukin (IL)-17, contribute to ischemic brain injury. As the intestine represents a major reservoir of γδ T cells, brain-gut communication may connect intestinal immune alterations with post-stroke neuroinflammation. This review examines the role of γδ T cells in ischemic stroke from the perspective of the brain-gut axis.
methodsWe synthesized current mechanistic evidence from experimental, translational, and clinical studies concerning γδ T-cell activation and recruitment after ischemic stroke. Particular attention was given to IL-17-mediated neuroinflammation, intestinal barrier dysfunction, gut microbiota dysbiosis, and bidirectional immune communication between the ischemic brain and the intestine.
resultsFollowing ischemic stroke, γδ T cells are activated and recruited to the injured brain, where their production of IL-17 promotes neuroinflammation, blood-brain barrier disruption, and secondary tissue injury. Concurrently, cerebral ischemia induces autonomic, immune, and metabolic disturbances that alter the gut microbiota and compromise intestinal barrier integrity. These changes may facilitate microbial product translocation and systemic inflammation, thereby amplifying cerebral inflammatory responses. Gut-resident γδ T cells may participate in this process by regulating mucosal immunity and IL-17-associated inflammatory signaling. Together, these mechanisms may establish a self-reinforcing brain-gut injury cycle. However, direct evidence defining the contributions, trafficking patterns, and functional heterogeneity of specific intestinal γδ T-cell subsets in ischemic brain injury remains limited.
conclusionsγδ T cells may serve as important immunological mediators linking intestinal dysfunction to neuroinflammation after ischemic stroke. Therapeutic strategies targeting γδ T-cell activation, IL-17 signaling, intestinal barrier disruption, or gut microbiota dysbiosis may help interrupt the brain-gut injury cycle. Future studies integrating lineage tracing, single-cell and spatial profiling, and tissue-specific interventions are required to distinguish the roles of brain-infiltrating and gut-resident γδ T-cell subsets and facilitate the clinical translation of brain-gut axis-based therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.